

Date: 17<sup>th</sup> March, 2019

To

The General Manager-Listing

Corporate Relationship

Department P J Towers,

Dalal Street,

Mumbai-400001

BSE Scrip Code: 540359

Dear Sir/Madam,

SUB: - OUTCOME OF BOARD MEETING

This is to notify that we hereby submitting the outcome of the Meeting of the Board of Directors held today, 17th March, 2019 at 12:00 p.m. at the Registered Office of the Company and was concluded at 7:30 p.m.:


1. Upon recommendation of Nomination and Remuneration Committee and subject to approval of Shareholders in General Meeting the Board has considered and approved the revision in remuneration of Mr. Alkesh M. Gopani, Managing Director w.e.f 1<sup>st</sup> April, 2019.
2. Upon recommendation of Nomination and Remuneration Committee and subject to approval of Shareholders in General Meeting the Board has considered and approved the revision in remuneration of Mr. Alkesh R. Gosalia, Managing Director (Finance and Operations) w.e.f. 1<sup>st</sup> April, 2019.
3. Upon recommendation of Nomination and Remuneration Committee and subject to approval of Shareholders in General Meeting the Board has considered and approved the revision in remuneration of Mr. Umang Alkesh Gosalia Whole-time Director w.e.f. 1<sup>st</sup> April, 2019.
4. Mr. Keyur Vora Chief Financial Officer informed the Board of Directors, at their meeting held today of his decision to step down from the post of Chief Financial Officer of the Company w.e.f. 30<sup>th</sup> April, 2019.

Please take the same on record.

Thanking You,

Yours Faithfully.

For, Parmax Pharma Limited

  
Yash J. Vora  
Company Secretary

